Human Immunology News Volume 4.05 | Feb 9 2016

Tumor-Derived Exosomes Regulate Expression of Immune Function-Related Genes in Human T Cell Subsets
Changes in the gene profiles of primary human T lymphocytes exposed in vitro to exosomes were evaluated. CD4⁺ Tconv, CD8⁺ T or CD4⁺ CD39⁺ Treg were isolated from normal donors’ peripheral blood and co-incubated with tumor cell-derived exosomes or exosomes isolated from supernatants of cultured dendritic cells. [Sci Rep] Full Article

An Adaptive Immune Response Driven by Mature, Antigen-Experienced T and B Cells within the Microenvironment of Oral Squamous Cell Carcinoma
For a deeper understanding of the role of the infiltrating-lymphocytes in oral squamous cell carcinoma, scientists characterized the lymphocyte infiltrate repertoires and defined their features. [Int J Cancer] Abstract

A Comparison of the Ability of the Human IgG1 Allotypes G1m3 and G1m1,17 to Stimulate T-Cell Responses from Allotype Matched and Mismatched Donors
Researchers investigated the potential of human IgG1 allotypes to stimulate responses in human CD4⁺ T cells from donors matched for homologous and heterologous IgG1 allotypes. [mAbs] Full Article

Secukinumab, a Novel Anti-IL-17A Antibody, Shows Low Immunogenicity Potential in Human In Vitro Assays Comparable to Other Marketed Biotherapeutics with Low Clinical Immunogenicity
To gain insight into possible explanations for the clinically observed low immunogenicity of secukinumab, investigators evaluated its immunogenicity potential by applying two different in vitro assays: T-cell activation and MAPPs (major histocompatibility complex–associated peptide proteomics). [mAbs] Abstract

Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis
Investigators utilized standard and next-generation sequencing techniques to investigate Epstein-Barr nuclear antigen-1 sequence variation and its relationship to HLA-DR15 binding affinity, and examined potential cross-reactive immune targets within the central nervous system proteome. [PLoS One] Full Article

Cytomegalovirus Infection Minimally Affects the Frequencies of B-Cell Phenotypes in Peripheral Blood of Younger and Older Adults
Researchers compared peripheral blood B-cell differentiation phenotypes of 140 age- and gender-matched cytomegalovirus (CMV)-seronegative or -seropositive adults aged between 24 and 85 years. They found that the frequencies of naïve B-cells within the CD19⁺ population were not significantly different in younger and older CMV-seronegative people. [Gerontology] Abstract

Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8⁺ and CD4⁺ T Cells
The authors report the superiority of CD40 over nine different lectins and scavenger receptors at evoking antigen-specific CD8⁺ T cell responses. However, lectins were more efficient than CD40 at eliciting CD4⁺ T cell responses. [EBioMedicine] Full Article

Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

Involvement of B Cells in Non-Infectious Uveitis
The authors summarize the evidence for B-cell involvement in non-infectious uveitis, and consider the potential contributions of B cells to the development and control of the disease. Manipulations of B cells and/or their products are promising new approaches to the treatment of non-infectious uveitis. [Clin Transl Immunol] Full Article

Visit our reviews page to see a complete list of reviews in the human immunology research field.

From our sponsor: Working with blood? Download the immune cell frequencies app.

Clinical Trial Offers New Drug Combo to Fight Lung Cancer
The Phase III clinical trial, called “Neptune,” compares a combination of two immune drugs with standard chemotherapy. It is one of the first clinical trials to test immune drugs as a first line treatment for lung cancer. [University of New Mexico Comprehensive Cancer Center] Press Release

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for Its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
TapImmune, Inc. announced that the U.S. Food & Drug Administration has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer. [TapImmune, Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the human immunology community.

NEW Senior/Principal Scientist – Antibody and Small Molecule Entities in Cellular Systems (UCB Pharma Ltd.)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellowship – Immunology (Beth Israel Deaconess Medical Center)

Faculty Positions – Immunology (University of Texas Health Science Center)

Professor – Human Immune-Defects (University of Bonn)

Postdoctoral Positions – Human Systems Immunology (University College Cork)

Postdoctoral Positions – Cancer Bioengineering and Biology (University of Minnesota)

Postdoctoral Position – Immunology (Indiana University School of Medicine)

Research Technician – CAR T Cell Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cell Therapy (Toronto Western Hospital)

Postdoctoral Positions – Hantavirus and Inflammation Research (Karolinska Institutet)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.